Parecoxib Minimum Age for Use
Parecoxib is not approved for use in children under 18 years of age, though research studies have evaluated its safety and efficacy in pediatric populations as young as 2-3 years. 1
Regulatory Status and Age Restrictions
- The FDA-approved prescribing information for parecoxib (valdecoxib prodrug) does not include approval for pediatric use, with the drug formally indicated only for adults aged 18 years and older 1
- Despite lack of formal pediatric approval, clinical research has investigated parecoxib use in children, with the youngest studied populations being 2-3 years of age 2, 3
Evidence from Pediatric Research Studies
Age ranges studied in clinical trials:
- A meta-analysis of pediatric parecoxib studies included children aged 2-12 years, demonstrating efficacy and safety for acute postoperative pain management 2
- A randomized controlled trial specifically evaluated children aged 3-7 years undergoing tonsillectomy, using parecoxib 1 mg/kg with favorable results 3
- Pharmacokinetic studies examined parecoxib in children aged 2-12 years, establishing dosing parameters across this age range 4
Dosing Considerations by Age (Based on Research)
For children 2-12 years (investigational use only):
- Doses of 0.25-2 mg/kg have been studied, with 1 mg/kg appearing optimal for postoperative analgesia 4
- Doses above 1 mg/kg provide no additional analgesic benefit 4
- Age-adjusted equivalent dosing: 0.9 mg/kg in 2-year-olds, 0.75 mg/kg in 7-year-olds, and 0.65 mg/kg in 12-year-olds achieves adult dose equivalence 4
Critical Safety Considerations
Important caveats for any off-label pediatric use:
- Clearance maturation may differ in infants younger than 2 years, making this age group particularly high-risk for off-label use 4
- No adequate safety or efficacy data exist for children under 2 years of age 2
- Renal function must be normal, as parecoxib/valdecoxib undergoes renal elimination 1
Clinical Bottom Line
In real-world practice, parecoxib should not be used in patients under 18 years without compelling justification, and never in children under 2 years where no safety data exist. If considering off-label use in children 2-17 years for postoperative pain, this represents an unapproved indication requiring informed consent discussion about lack of regulatory approval, despite research suggesting reasonable safety in the 2-12 year age range 2, 3, 4.